174 results about "Hybrid protein" patented technology

The invention relates to improved methods for directed evolution of polymers, including directed evolution of nucleic acids and proteins. Specifically, the methods of the invention include analytical methods for identifying "crossover locations" in a polymer. Crossovers at these locations are less likely to disrupt desirable properties of the protein, such as stability or functionality. The invention further provides improved methods for directed evolution wherein the polymer is selectively recombined at the identified "crossover locations". Crossover disruption profiles can be used to identify preferred crossover locations. Structural domains of a biopolymer can also be identified and analyzed, and domains can be organized into schema. Schema disruption profiles can be calculated, for example based on conformational energy or interatomic distances, and these can be used to identify preferred or candidate crossover locations. Computer systems for implementing analytical methods of the invention are also provided.

The invention provides an inactivated Zika virus vaccine. The inactivated Zika virus vaccine is obtained by: performing ultrafiltration and concentration on Zika virus liquid after inactivation, centrifuging the concentrated virus liquid by adopting a sucrose density zone, performing ion exchange and concentration sterilization on a centrifugal product to obtain a Zika virus vaccine stock solution, diluting the vaccine stock solution until the total protein content is not more than 20mu g/ml, and adding an adjuvant to obtain a vaccine semi-finished product. The method for preparing the vaccine provided by the invention is simple, convenient and easy to operate, the cost is saved, the produced vaccine is suitable for Asian people, a unit dose of the Zika virus liquid is high in immunogenicity, the content of hybrid protein is low, the side effect after injection is small, and the safety is high, so that the vaccine is suitable for vaccination of fertile women before pregnancy, can avoid newborn Brazil microcephaly caused by infection of Zika virus, and is significant in social value and market efficiency.

The invention discloses a method for preparing low-molecular-weight aquatic collagen peptides. Fresh fish scales are delimed with hydrochloric acid, fat and impurities are removed with caustic soda, and then hot water extraction is carried out to obtain a collagen solution, and three kinds of enzymes are used to separate enzyme Decompose collagen, then carry out activated carbon filtration and macroporous resin treatment, collect decolorization liquid, filter through ultrafiltration membrane, freeze-dry, the effective method of preparation molecular weight concentration, high recovery rate, good decolorization effect fish scale low molecular weight collagen, not only can Obtain high-content low-molecular-weight collagen peptides from fish skin and fish scales, remove pigments that affect the appearance of collagen products, and reduce the unique fishy smell of collagen, which can improve the product value of fish collagen products.

The invention provides II-type collagen joint cartilage fluid and a preparation method thereof. Bacteria, viruses and other hazardous substances of the joint cartilage are removed through degreasing-> serum removing-> surfactant treatment-> oxidant treatment-> disinfection and other links. Hybrid protein and other denatured protein of the cartilage are removed through acid hydrolysis, salt precipitation, dialysis and other processes, and high-purity and high-activity II-type collagen solution is prepared. Non-toxin and non-heat raw materials and auxiliary materials and isotonic solution are mixed in an appropriate ratio, and filled in a sterile non-heat disposable injector, to prepare II-type collagen joint cartilage fluid for disposable injection. Other components of the II-type collagen joint cartilage fluid comprise the auxiliary materials and the isotonic solution. The II-type collagen joint cartilage fluid can play the roles of lubrication, pain relieving and joint activity degree improving to the injured joints, fundamentally realizes the internal repair to the cartilage tissue, and is applicable to a patient with various joint cartilage injuries and all types of arthritis.

The invention discloses a process for producing recombinant alpha-cyclodextrin glucosyltransferase in a fermenting way by culturing escherichia coli in high density through a temperature two-stage control strategy and a constant oxygen-dissolved and feed-supplemented batch technology, belonging to the technical field of fermentation engineering. The method comprises the following steps of: inoculating recombinant escherichia coli BL21(DE3) as a production strain at the inoculation quantity of 5-10 percent and fermenting in batch; starting adding a supplementing liquid in a flowing mode when dissolved oxygen rises to about 80-100 percent, ensuring that a strain body exponentially grows, controlling the temperature of the growth phrase of the strain body to be 33-37DEG C and maintaining the dissolved oxygen to 20-30 percent; adding 0.75-1.5 percent (mass volume percent) of glycine when the strain body OD600 reaches about 15-30; reducing the temperature to be 23-27DEG C and continuously supplementing 0.2-0.4g.l<-1>.h<-1> when the strain body OD600 reaches 45-60 and supplementing the supplementing liquid by adopting a gradient diminishing mode at the same time; and enabling the enzymeactivity of the extracellular alpha-cyclodextrin glucosyltransferase to reach 200-280U/ml by fermenting culture for 30-35 hours. By adopting the strategy to ferment, the invention realizes the high-efficiency extracellular expression of the alpha-cyclodextrin glucosyltransferase and greatly improves the production intensity. The invention has the advantages of wide source of raw materials, simple and feasible process and suitability for large-scale production; with effective extracellular expression, the pollution on host bacteria hybrid proteins can be greatly reduced and the purification efficiency of the protein can be improved. The invention lays a foundation for large-scale production of the alpha-cyclodextrin glucosyltransferase.

The invention discloses a preparation method of Lumbrokinase, comprising the steps of grinding, deslagging, salting-out, centrifuging, ultra-filtrating, column chromatography isolating, ultra-filtrating, degerming, spray-drying and the like. The preparation method of Lumbrokinase provided by the invention is that ethanol is added as adjuvant to remove hybrid protein by physical settlement and ultrafiltration during the homogenate of earthworms, and then a column chromatography purification is performed so that the capacity of the column is reduced, thereby the yield of the Lumbrokinase is increased, the preparation cost is reduced, the waste fluid to be treated is decreased and the production capacity is increased greatly. The preparation method of Lumbrokinase has the characteristics of good quality controllability and stability of the production process.

A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and mast cell degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-Ile-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

The invention relates to a method for fast enzymolysis of hybrid proteins comprising: providing protein samples to be enzymolysis; obtaining the denatured protein samples after the degeneration treatment of said protein samples; treating said denatured protein samples by means of protease enzymolysis and assistant with ultrasonic, obtaining the protein polypeptide fragments. The invention also provides a method for fast identifying the protein. The method of the invention can quickly and high efficiently implement the protein enzymolysis and identification with easy operation and high accuracy.

The invention discloses alkaline pectate lyase producing gene engineering bacteria and construction and use thereof and belongs to the field of genetic engineering. In the invention, the Escherichia coli pel engineering bacteria capable of secreting and expressing pectinase Pel in vitro with high efficiency are constructed from an industrial prospective by using a totally synthetic Aspergillus nidulans pel gene. The invention also provides a method for producing pectinase by using the engineering bacteria. When the engineering bacteria are used, the fermentation time is short, and at 37 DEG C, the total fermentation lasts for 6 hours, wherein the early fermentation lasts for 4 hours and post fermentation lasts for 6 hours; the enzyme active yield is as high as 400U/mL; in addition, the produced pectinase can be secreted in vitro directly, hybrid proteins are reduced, and the purification is easy. Therefore, the engineering bacteria have better industrial application prospect.

Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or by employing a biologic resurfacing mold, for example) into, or in the vicinity of, the anatomical tissue. Upon insertion within, or contact with, the anatomical tissue, the biological component/glue composition is designed to coagulate and solidify (or partially solidify) within minutes, to advance healing or tissue growth of the anatomical tissue. The biological component/glue composition may optionally comprise components such as growth factors, antiseptic chemicals and/or antibiotics and/or electrolytes, or hormones or site-specific hybrid proteins, among others.

A method and a kit for detecting interactions between three or more proteins, in vivo, using reconstitution of the activity of a transcriptional activator is provided. Reconstitution of the transcriptional activator makes use of chimeric genes which express hybrid proteins. In one embodiment, three types of hybrid proteins are prepared. The first hybrid contains the DNA-binding domain of a transcriptional activator fused to the first test protein. The second hybrid protein contains a transcriptional activation domain fused to the second test protein. The third hybrid protein contains a nuclear localization peptide fused to a third test protein and mediates assembly of the three-protein complex involving the three hybrids. If the three test proteins are able to interact, they bring into close proximity the two domains of the transcriptional activator. This proximity is sufficient to cause transcription, which can be detected by the activity of a marker gene that contains a binding site for the DNA-binding domain.

The invention discloses a simple and quick method for improving separation efficiency, purity and biological specific activity of blood coagulation factor VIII and an analog thereof. The method is based on application of an affine aqueous two-phase technology, i.e., a characteristic hydrophilic macromolecular compound, preferably polyethylene glycol (PEG), forms a stable aqueous two-phase system with phosphate, glucan or other second component in aqueous solution; and one of core technologies is that: covalent linkage of the PEG and the blood coagulation factor VIII specific affine small peptide ligand is realized. The blood coagulation factor VIII is preferably located in a characteristic hydrophilic macromolecular compound phase connected to the affine small peptide ligand; and most of protein (or hybrid protein) from cell extract tends to move to another phase. By changing existence of target protein or polypeptide in one phase or another phase, the protein or polypeptide is efficiently purified with high purity.

Disclosed is a hybrid protein-polysaccharide superabsorbent hydrogel. The hydrogel includes two interpenetrating matrices: a first matrix which is an acylated, cross-linked protein matrix, and a second matrix which is an anionic polysaccharide matrix. The two matrices can be non-cross-linked, or the hydrogel can further include bridging moieties that covalently cross-linking the acylated, cross-linked protein matrix to the anionic polysaccharide matrix.

The invention discloses expression and preparation methods for a bivalent bispecific antibody and a hybrid protein and belongs to the technical field of biology. According to the methods, the aim of preparing products, i.e., the bivalent bispecific antibody and the immune hybrid protein thereof are prepared through expressing all parts of the bivalent bispecific antibody and the immune hybrid protein thereof separately in appropriate procaryotic or eucaryotic cell systems, carrying out high-performance affinity-chromatography purification and separation, and then, carrying out splicing in vitro under the condition of intein splicing. The methods have high production efficiency, are wide in applicable application range and facilitate the separation and purification of the products. The products prepared by using the methods have biological activities, i.e., bivalent bispecific immunoaffinity and cytotoxicity. The methods are novel methods for preparing biological drugs for directional attack on cancers or other diseases.

The invention discloses a method for separating purified gamma-polyglutamic acid from fermentation liquor. The method comprises the following steps of: firstly, diluting the fermentation liquor by using water and regulating the pH value to 2.8-3.2; carrying out plate filter for degerming, and regulating the pH value of filter liquor to 6.9-7.3; carrying out alcohol precipitation and removing water in the precipitate; centrifuging to separate out the precipitate as well as decompressing and drying to obtain a crude gamma-polyglutamic acid product; dissolving again and regulating the pH value to 6.9-7.1; adding protease, preserving heat and removing hybrid protein; regulating the pH value to 2.9-3.1 and ultra-filtering to remove pigment and micromolecule impurities; regulating the pH value to 6.9-7.1 and carrying out alcohol precipitation; and decompressing and drying to obtain a finished high-purity gamma-polyglutamic acid product. In the invention, the purposes of separating and purifying high-purity gamma-polyglutamic acid are achieved through regulating the pH values, centrifuging, precipitating and filtering in multiple steps. The method has the advantages of high purity, high yield, low cost and environmental protection.

The invention provides a low-serum culture medium suitable for the growth of Vero cells. The dosage of calf serum for conventional culture is reduced to 2 percent from 10 percent (which is the contentof a component V), and conventionally added animal derived components are replaced with plant derived components and recombinant protein. According to the low-serum culture medium provided by the invention, the dosage of the serum is reduced, so that the cost is reduced, and the possibility that the serum in the culture medium carries exogenous pathogenic bacterium pollution is reduced; meanwhile, a lot of hybrid proteins in the serum are reduced and separation and purification of down-stream products are facilitated; plant hydrolyzed protein and recombinant endothelial growth factors are used for replacing the animal derived components so that the side effect of the animal derived components is reduced and the safety of biological products is improved. According to the culture medium provided by the invention, the Vero cells grow well and the cost is reduced; the exogenous pathogenic bacterium pollution is reduced, a post-period purification technology is reduced and the stability ofproducing cell products is improved; one good-quality culture medium is provided for producing the biological products which take the Vero cells as virus hosts or expression vectors.